(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-3.32%) $1.920
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
Live Chart Being Loaded With Signals
Eisai Co., Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer's disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures...
Stats | |
---|---|
Šios dienos apimtis | 4.00 |
Vidutinė apimtis | 1 120.00 |
Rinkos kapitalizacija | 11.48B |
EPS | $9.72 ( 2023-11-06 ) |
Last Dividend | $0.603 ( 2023-03-30 ) |
Next Dividend | $0 ( N/A ) |
P/E | 39.22 |
ATR14 | $0 (0.00%) |
Eisai Co., Ltd. Koreliacija
10 Labiausiai teigiamai susiję koreliacijos |
---|
10 Labiausiai neigiamai susiję koreliacijos |
---|
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Eisai Co., Ltd. Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $744.40B |
Bruto pelnas: | $543.48B (73.01 %) |
EPS: | $193.31 |
FY | 2023 |
Pajamos: | $744.40B |
Bruto pelnas: | $543.48B (73.01 %) |
EPS: | $193.31 |
FY | 2022 |
Pajamos: | $756.23B |
Bruto pelnas: | $569.79B (75.35 %) |
EPS: | $167.27 |
FY | 2021 |
Pajamos: | $645.94B |
Bruto pelnas: | $484.63B (75.03 %) |
EPS: | $146.95 |
Financial Reports:
No articles found.
Eisai Co., Ltd. Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0.555 (N/A) |
$0 (N/A) |
$0.603 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | $0.784 | 2014-03-27 |
Last Dividend | $0.603 | 2023-03-30 |
Next Dividend | $0 | N/A |
Payout Date | 2018-05-24 | |
Next Payout Date | N/A | |
# dividends | 18 | -- |
Total Paid Out | $11.60 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 2.79 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 4.00 | |
Div. Directional Score | 7.04 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
WJRYF | Ex Dividend Knight | 2023-09-28 | Annually | 0 | 0.00% | |
MCBK | Ex Dividend Junior | 2023-05-02 | Annually | 0 | 0.00% | |
CMSQY | Ex Dividend Knight | 2023-08-22 | Annually | 0 | 0.00% | |
SOBS | Ex Dividend Knight | 2023-06-29 | Quarterly | 0 | 0.00% | |
HCMLY | Ex Dividend Knight | 2023-05-09 | Annually | 0 | 0.00% | |
AMNF | Ex Dividend King | 2023-07-06 | Quarterly | 0 | 0.00% | |
NLCP | Ex Dividend Knight | 2023-09-28 | Quarterly | 0 | 0.00% | |
CTUY | Ex Dividend Junior | 2023-05-24 | Annually | 0 | 0.00% | |
THNPF | Ex Dividend Knight | 2023-05-22 | Annually | 0 | 0.00% | |
IDCBY | Ex Dividend Junior | 2023-07-06 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0606 | 1.500 | 8.79 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0346 | 1.200 | 8.85 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.0546 | 1.500 | -0.504 | -0.756 | [0.1 - 1] |
payoutRatioTTM | 1.011 | -1.000 | 10.00 | -10.00 | [0 - 1] |
currentRatioTTM | 2.38 | 0.800 | 3.10 | 2.48 | [1 - 3] |
quickRatioTTM | 1.697 | 0.800 | 4.72 | 3.78 | [0.8 - 2.5] |
cashRatioTTM | 1.025 | 1.500 | 5.42 | 8.12 | [0.2 - 2] |
debtRatioTTM | 0.127 | -1.500 | 7.89 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 25.36 | 1.000 | 1.719 | 1.719 | [3 - 30] |
operatingCashFlowPerShareTTM | 215.91 | 2.00 | 10.00 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 166.26 | 2.00 | 10.00 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.203 | -1.500 | 9.19 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.789 | 1.000 | 0.176 | 0.176 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0790 | 1.000 | -0.419 | -0.419 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.372 | 1.000 | 9.04 | 9.04 | [0.2 - 2] |
assetTurnoverTTM | 0.572 | 0.800 | 9.52 | 7.62 | [0.5 - 2] |
Total Score | 10.08 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 39.99 | 1.000 | 6.06 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0546 | 2.50 | -0.324 | -0.756 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 166.26 | 2.00 | 10.00 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0.0168 | 1.500 | 9.58 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 215.91 | 2.00 | 10.00 | 10.00 | [0 - 30] |
payoutRatioTTM | 1.011 | 1.500 | 10.00 | -10.00 | [0 - 1] |
pegRatioTTM | 0.0162 | 1.500 | -3.23 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.0826 | 1.000 | -0.434 | 0 | [0.1 - 0.5] |
Total Score | 4.00 |
Eisai Co., Ltd.
Eisai Co., Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer's disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures. The company also provides Lyrica for pain treatment; Dayvigo, an anti-insomnia drug for the treatment of adults with insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; and Halaven, an anticancer agent/microtubule dynamics inhibitor for the treatment of breast cancer and liposarcoma. In addition, it offers Pariet, a proton-pump inhibitor for the treatment of gastric and duodenal ulcers, reflux esophagitis, and eradication of Helicobacter pylori infections, etc.; Humira, a fully human anti-TNF-a monoclonal antibody for the treatment of autoimmune diseases, such as rheumatoid arthritis; and Chocola BB plus, a vitamin B2 preparation for rough skin and stomatitis, as well as various products, which include third-class OTC drugs, designated quasi-drugs, and food with nutrient function. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.